“…Development of XO inhibitors with free radical scavengers potential may prove to be promising agents to treat Gout. This encouraged the researchers to develop structurally diverse molecules without purine backbone with promising XO inhibitory activity such as N‐(1,3‐diaryl‐3‐oxopropyl) amides ( 4 ) ,1‐acetyl‐3,5‐diaryl‐4,5‐di‐hydrol(1H) pyrazoles ( 5 ) , Y‐700 ( 6 ) , N‐aryl‐5‐amino‐4‐cyanopyrazole (7) , flavonoids ( 8 ) , anacardic acid ( 9) , thiazolo‐pyrazolyl 5‐phenylisoxazole‐3‐carboxylic acid ( 10 ) , naphthoflavones ( 11 ) , and pyrazolo[3,4‐d] thiazolo[3,2‐a]pyrimidin‐4‐one ( 12 ) , 2‐(3‐cyano‐2‐isopropyl‐1H‐indol‐5‐yl)‐4‐methylthiazole‐5‐carboxylic acid ( 13 ) , derivatives (Figure ). It was assumed worthwhile to rationally design with pharmacophoric approaches to develop structural analogous of febuxostat as non‐purine XO inhibitors with antioxidant activity for diminishing the associated toxicities.…”